Frontiers: University of Kansas Clinical and Translational Science Institute
前沿:堪萨斯大学临床与转化科学研究所
基本信息
- 批准号:9560956
- 负责人:
- 金额:$ 402.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-07 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAddressAdvocacyAdvocateAfrican AmericanAmerican IndiansAutomobile DrivingAwardBirthChildhoodCitiesClinicClinicalClinical ResearchClinical SciencesCollaborationsCommunitiesCompetenceComplexDataData AnalysesDecision MakingDevelopmentDisciplineDiseaseElderlyElectronic Health RecordEnsureEntrepreneurshipEthicsFundingGenerationsGoalsGood Clinical PracticeGovernmentHealthHealth SciencesHealthcareIndividualIndustryInformaticsInformation DisseminationInstitutesInstitutionInstitutional Review BoardsInterdisciplinary StudyKansasKnowledgeLatinoLeadLeadershipLinkLongevityMedicalMedical DeviceMedical InformaticsMedical centerMethodsMidwestern United StatesParticipantPatientsPharmaceutical PreparationsPilot ProjectsPopulation HeterogeneityPositioning AttributePrisonsProcessRare DiseasesRegistriesResearchResearch DesignResearch InfrastructureResearch PersonnelResearch SupportResearch TrainingResource InformaticsResourcesRural PopulationScienceScientific Advances and AccomplishmentsTexasTrainingTraining ProgramsTranslatingTranslational ResearchUniversitiesVisionWorkforce Developmentbasecatalystclinical carecommunity partnershipdrug discoveryend of lifefrontierimplementation researchimprovedindustry partnerinnovationmulti-site trialmultidisciplinarynext generationnovelnovel strategiespatient engagementpatient orientedpoint of carepopulation healthprecision medicineproduct developmentprogramsrecruitservice organizationsupport toolstool
项目摘要
Contact PD/PI: Barohn, Richard Joel
OVERALL: ABSTRACT
Frontiers: The Heartland Institute for Clinical and Translational Research has been a catalyst for bringing
together translational science investigators and stakeholders across the KC region, and beyond. Located
at the University of Kansas Medical Center (KUMC) under the leadership of Dr. Barohn, our commitment
to team science and multidisciplinary collaboration reaches beyond the walls of our academic health
science center and promotes collaboration among investigators from diverse disciplines across local
partner academic institutions and affiliated health care institutions. The vision of Frontiers is to contribute
to and lead national efforts to transform the way we do clinical and translational research (CTR), and to
ensure research is more rapidly and more efficiently translated to the point of care so that it may contribute
to improved health. Specifically, Frontiers aims to: 1) Engage in bi-directional collaboration with all
stakeholders to develop, demonstrate, and disseminate advances across the translational science
spectrum that insures inclusion and integration of complex and diverse populations and individuals across
the lifespan from birth to end of life; 2) Create a sustainable translational workforce of multi-disciplinary
investigators, research personnel, and community and patient stakeholders in the use of translational
science tools through innovative and creative programs; and 3) Strengthen institutional and regional
infrastructure to accelerate translational research. We will accomplish these aims by drawing on our
considerable strengths: a) developing informatics tools for making EHR data `research ready' and
implementing clinic- and community-based registries for study recruitment and other translational research
applications; b) nurturing and sustaining strong patient and community engagement relationships that will
support research with African American, Latino, American Indian, LGBTQ, pediatric, geriatric, rare
disease, prison, and rural populations; c) offering innovative training programs for the entire CTR
workforce (not just investigators), including plans for comprehensive entrepreneurship and implementation
research training and creating new team science brainstorming mechanisms that will lead to
multidisciplinary discovery projects and d) advancing medical devices and re-purposed drugs to patients
through novel strategies developed by Frontiers' Institute for Advancing Medical Innovations (IAMI)that is
nationally known for its product development translational research and high impact collaborations with
industry, academia, government, and disease philanthropy partners. All Frontiers units are linked by a
group of Navigators that can be accessed by Frontiers investigative teams and community partners.
These plans position Frontiers to contribute to goals, and lead initiatives of the CTSA network by building
on technological, computational, and health/disease knowledge to advance translational research.
Project Summary/Abstract Page 274
Contact PD/PI: Barohn, Richard Joel
OVERALL NARRATIVE
Frontiers: The Heartland Institute for Clinical and Translational Research provides infrastructure and
educational programs to develop the next generation of CTR investigative teams. As a regional organization
involving two states and three universities, Frontiers is able to blend the best resources available to advance
team, community and clinical translational science. This results in accelerating discoveries and research
findings that may be more rapidly brought to the point of care and contribute to population health.
联系人 PD/PI:Barohn、Richard Joel
总体:摘要
前沿:Heartland 临床和转化研究所一直是推动
堪萨斯城地区及其他地区的转化科学研究者和利益相关者共同努力。位于
在 Barohn 博士的领导下的堪萨斯大学医学中心 (KUMC),我们的承诺
团队科学和多学科合作超越了我们学术健康的范围
科学中心,并促进当地不同学科的研究人员之间的合作
合作学术机构和附属医疗保健机构。 Frontiers 的愿景是贡献
领导国家努力改变我们进行临床和转化研究(CTR)的方式,并
确保研究更快速、更有效地转化为护理点,以便它可以做出贡献
改善健康状况。具体来说,Frontiers 的目标是: 1) 与所有各方进行双向合作
利益相关者开发、展示和传播转化科学的进步
确保包容和融合复杂多样的人口和个人的频谱
从出生到生命终结的寿命; 2) 创建一支可持续的多学科翻译队伍
研究者、研究人员以及社区和患者利益相关者在使用转化技术时
通过创新和创意项目的科学工具; 3) 加强机构和区域
加速转化研究的基础设施。我们将通过利用我们的资源来实现这些目标
相当大的优势:a) 开发信息学工具,使 EHR 数据“为研究做好准备”
实施基于临床和社区的研究招募和其他转化研究登记
应用程序; b) 培育和维持牢固的患者和社区参与关系,这将
支持非裔美国人、拉丁裔、美洲印第安人、LGBTQ、儿科、老年、罕见的研究
疾病、监狱和农村人口; c) 为整个 CTR 提供创新的培训计划
劳动力(不仅仅是调查人员),包括全面创业和实施的计划
研究培训和创建新的团队科学集思广益机制,这将导致
多学科发现项目和 d) 向患者推进医疗设备和重新利用药物
通过前沿医学创新促进研究所 (IAMI) 制定的新颖策略,
以其产品开发转化研究和与以下机构的高影响力合作而闻名全国
工业界、学术界、政府和疾病慈善事业合作伙伴。所有 Frontiers 单位都通过一个
Frontiers 调查团队和社区合作伙伴可以访问的导航器组。
这些计划使 Frontiers 能够为目标做出贡献,并通过构建 CTSA 网络来领导 CTSA 网络的举措
技术、计算和健康/疾病知识,以推进转化研究。
项目摘要/摘要第 274 页
联系人 PD/PI:Barohn、Richard Joel
整体叙述
前沿:Heartland 临床和转化研究所提供基础设施和
培养下一代 CTR 调查团队的教育计划。作为一个区域组织
Frontiers 涉及两个州和三所大学,能够整合可用的最佳资源来推进
团队、社区和临床转化科学。这会加速发现和研究
这些发现可能会更快地送到护理点并有助于人口健康。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard J. Barohn其他文献
Richard J. Barohn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard J. Barohn', 18)}}的其他基金
Frontiers: University of Kansas Clinical and Translational Science Institute
前沿:堪萨斯大学临床与转化科学研究所
- 批准号:
9514338 - 财政年份:2017
- 资助金额:
$ 402.38万 - 项目类别:
Models of Neuromuscular Disease Across the Lifespan
整个生命周期的神经肌肉疾病模型
- 批准号:
9195818 - 财政年份:2016
- 资助金额:
$ 402.38万 - 项目类别:
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
美金刚治疗肌萎缩侧索硬化症的 2B 期试验
- 批准号:
9341908 - 财政年份:2013
- 资助金额:
$ 402.38万 - 项目类别:
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
美金刚治疗肌萎缩侧索硬化症的 2B 期试验
- 批准号:
8683099 - 财政年份:2013
- 资助金额:
$ 402.38万 - 项目类别:
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
美金刚治疗肌萎缩侧索硬化症的 2B 期试验
- 批准号:
8569903 - 财政年份:2013
- 资助金额:
$ 402.38万 - 项目类别:
A Phase II Trial of Rituximab In Myasthenia Gravis
利妥昔单抗治疗重症肌无力的 II 期试验
- 批准号:
8731286 - 财政年份:2013
- 资助金额:
$ 402.38万 - 项目类别:
A Phase II Trial of Rituximab In Myasthenia Gravis
利妥昔单抗治疗重症肌无力的 II 期试验
- 批准号:
8644497 - 财政年份:2013
- 资助金额:
$ 402.38万 - 项目类别:
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
美金刚治疗肌萎缩侧索硬化症的 2B 期试验
- 批准号:
10242456 - 财政年份:2013
- 资助金额:
$ 402.38万 - 项目类别:
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis
雷沙吉兰治疗肌萎缩侧索硬化症的 2 期研究
- 批准号:
8355588 - 财政年份:2012
- 资助金额:
$ 402.38万 - 项目类别:
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis
雷沙吉兰治疗肌萎缩侧索硬化症的 2 期研究
- 批准号:
8543461 - 财政年份:2012
- 资助金额:
$ 402.38万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
NIDA Clinical Trials Network: New York Node
NIDA 临床试验网络:纽约节点
- 批准号:
10855627 - 财政年份:2023
- 资助金额:
$ 402.38万 - 项目类别:
Addressing Surgical Disparities at the Root; Working to improve diversity in the surgical workforce
从根本上解决手术差异;
- 批准号:
10639471 - 财政年份:2023
- 资助金额:
$ 402.38万 - 项目类别:
NIDA Clinical Trials Network: New York Node - GY22 Integrating MOUD in Non-Medical Settings to Improve Treatment and Retention of Black/AA Persons
NIDA 临床试验网络:纽约节点 - GY22 在非医疗环境中整合 MOUD,以改善黑人/AA 人的治疗和保留
- 批准号:
10809985 - 财政年份:2023
- 资助金额:
$ 402.38万 - 项目类别:
Applied Curriculum in Gender and Equity Skills (ACES)
性别与平等技能应用课程(ACES)
- 批准号:
10731498 - 财政年份:2023
- 资助金额:
$ 402.38万 - 项目类别:
Training in Neurotherapeutics for Academic Scientists
学术科学家神经治疗学培训
- 批准号:
10666685 - 财政年份:2022
- 资助金额:
$ 402.38万 - 项目类别: